VCANBIO(600645)2022-04-24 16:00Financial Performance - The company's operating revenue for Q1 2022 was RMB 394,174,107.03, representing a year-on-year increase of 7.50%[6] - The net profit attributable to shareholders of the listed company was RMB 35,823,760.85, showing a decrease of 21.36% compared to the same period last year[6] - The basic and diluted earnings per share were both RMB 0.08, reflecting a decline of 20.00% year-on-year[6] - Net profit for Q1 2022 was approximately RMB 36.25 million, a decrease of 20.9% from RMB 45.81 million in Q1 2021[34] - The total equity attributable to shareholders decreased to approximately RMB 3.42 billion in Q1 2022 from RMB 3.46 billion in Q1 2021, a decline of 1.2%[32] - The total comprehensive income attributable to the parent company was -42,619,357.36 CNY, compared to 198,663,061.28 CNY in the previous year, indicating a significant decline[37] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 38.83% to RMB 30,064,712.75, primarily due to increased procurement costs and higher performance bonuses paid to employees[11] - The net cash flow from operating activities was 30,064,712.75 CNY, down from 49,151,166.35 CNY year-over-year, reflecting a decrease of approximately 38.9%[41] - Cash received from the sale of goods and services was 395,390,920.90 CNY, an increase of 4.1% from 380,293,037.07 CNY in the previous year[41] - The total cash outflow from operating activities was 372,444,440.55 CNY, compared to 337,776,132.89 CNY in the previous year, reflecting an increase of approximately 10.2%[41] - The cash outflow from financing activities was 8,739,581.93 CNY, compared to 2,489,757.56 CNY in the previous year, indicating a significant increase in cash outflow[43] - The net cash flow from investment activities was -24,442,765.20 CNY, an improvement from -69,072,037.84 CNY in the previous year, showing a reduction in cash outflow from investments[41] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,042,570,476.68, a slight increase of 0.18% from the end of the previous year[9] - The company's total liabilities increased to approximately RMB 1.55 billion in Q1 2022 from RMB 1.50 billion in Q1 2021, reflecting a growth of 3.7%[30] - As of March 31, 2022, the total current assets amounted to RMB 2,083,470,848.81, an increase from RMB 2,030,210,899.72 at the end of 2021[27] - The company's non-current assets totaled RMB 2,959,099,627.87, down from RMB 3,003,166,772.38 at the end of 2021[27] - The company's accounts receivable increased to RMB 498,494,250.32 from RMB 456,387,269.65 at the end of 2021, reflecting a growth of approximately 9.1%[27] - The company reported a decrease in cash and cash equivalents to RMB 1,190,853,808.99 from RMB 1,195,655,271.02 at the end of 2021[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 38,735[14] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares, amounting to 56,787,503 shares[14] Investments and Agreements - The company invested RMB 20 million in Shanghai Zhongyuan Jisheng Cell Technology Co., holding a 50% equity stake after the capital increase[19] - The company signed a real estate lease agreement with Shanghai Yanlan Biotechnology Co., with an annual rent of RMB 7,256,784 for a 5,232 square meter property[22] - The total rental payment after discounts is RMB 60,956,985.60, with the first payment of RMB 17,960,540.40 due initially[22] Research and Development - Research and development expenses for Q1 2022 were approximately RMB 29.03 million, slightly down from RMB 29.77 million in Q1 2021[32] Other Financial Metrics - Non-recurring gains and losses totaled RMB 379,000.08 for the period, with government subsidies contributing RMB 273,114.23[10] - The weighted average return on net assets was 1.04%, a decrease of 0.26 percentage points compared to the previous year[6] - The company's deferred income tax liabilities were approximately RMB 34.12 million in Q1 2022, slightly down from RMB 34.70 million in Q1 2021[30] - The total comprehensive income for Q1 2022 included a significant other comprehensive loss of approximately RMB 78.44 million, contrasting with a gain of RMB 153.11 million in Q1 2021[34] - The company's cash and cash equivalents were not explicitly stated but are implied to be part of the overall financial health reflected in the total assets of approximately RMB 5.04 billion[32] - The company reported a credit impairment loss of approximately RMB 5.32 million in Q1 2022, compared to RMB 6.07 million in Q1 2021, indicating an improvement[34]